agenT-797: Clinical Trials

1 trial of agenT-797, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 withdrawn. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Withdrawn 1

Follow agenT-797: new trials by email Literature Review of agenT-797 trials Research Report on agenT-797

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
Nogapendekin alfa inbakicept (NAI), agenT-797 - Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Phase 3WithdrawnImmunityBio, Inc.2026-04-152026-05-08

Conditions studied

Community-Acquired Pneumonia (1)  ·  Critical Illness (1)  ·  Lymphopenia (1)  ·  Respiratory Distress Syndrome (1)  ·  Sepsis (1)

Sponsors

ImmunityBio, Inc. (1)

Top investigators

Jayson Garmizo (1)